Mounjaro®
Starting from £179.99/mo
Start journey Learn moreThe stomach is the most commonly used site for Mounjaro injections, and for good reason: there is plenty of subcutaneous fat, the area is easy to reach, and absorption tends to be consistent. Your prescriber and the Patient Information Leaflet confirm that the abdomen, thigh and upper arm are all licensed injection sites — rotating between them matters as much as the site you pick. These are prescription-only injections; a prescriber assesses which site guidance applies to your situation. Read on for the practical detail.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
The abdominal wall carries a generous layer of subcutaneous fat in most adults, which makes it forgiving. The needle reaches the right tissue depth without the angulation that can be needed at the thigh or arm, and you can see exactly what you're doing. That visibility is one reason clinicians and the NHS tirzepatide guidance consistently list the abdomen first.
That said, the stomach is not compulsory. If you have very little abdominal fat, if scar tissue from previous surgery covers the area, or if rotating stomach sites has left your skin lumpy or tender, the thigh or upper arm are clinically equivalent alternatives. The SmPC is explicit: all three sites are suitable. The choice is yours week to week, provided you keep moving around.
One thing to clear up early: our page on where to inject Mounjaro in the stomach explains that injecting into the stomach means the subcutaneous fat layer of the abdomen, not the stomach organ. The needle is short (typically 4–5 mm) and it goes just under the skin. Muscle lies much deeper and is not the target.
Picture the abdomen as a rectangle below your ribcage and above your hip bones. The two zones most people use are the lower quadrants (the soft areas to the left and right of the navel) because fat tends to be most accessible there. Keep at least two inches (about 5 cm) away from the navel itself; the tissue there is denser and absorption can be less predictable. More detailed placement guidance is covered in our page on where in the stomach to inject Mounjaro.
Avoid any patch of skin that is bruised, inflamed, broken or scarred. Active stretch marks are best skirted, and the waistband area (anywhere clothing sits tight and rubs) is worth giving a wide berth. If you wear an insulin pump or CGM sensor, keep your injection at least three centimetres away from the device.
Before injecting, clean the site with an alcohol swab and let it dry completely, damp skin can sting and interfere with adhesion. Our alcohol swabs are stocked for this purpose if you need them.
Using the same small patch every week is one of the more common mistakes clinicians see with injectable medicines. Repeated injections into identical spots cause the fatty tissue to thicken, a condition called lipohypertrophy. Thickened tissue absorbs medicine unpredictably, which means you might be getting less tirzepatide than you think even when you are injecting correctly. That is a practical safety point, not a theoretical one.
A simple rotation pattern: divide the abdomen into a rough clock face and move one position clockwise each week. When you have worked around the clock, shift to the thigh for a week or two, then back. Some people find it helpful to map their sites on a printed body diagram. Whatever system you use, the point is that no single spot gets a needle two weeks running.
Each Mounjaro KwikPen contains four weekly doses at the same strength, so you will use it for four consecutive weeks before moving to the next pen. That is four injections per pen, four sites to plan. The pen that arrives from our pharmacy in plain DPD packaging has a built-in needle guard; dispose of used needles promptly in a sharps container rather than the household bin.
The Mounjaro KwikPen is designed to make this straightforward. You do not need to pinch the skin in most cases, if you have enough subcutaneous fat at the site, hold the pen at a 90-degree angle, press it flat to the skin, and activate the injection. If you are very lean in that area, a gentle skin fold can help the needle reach subcutaneous rather than intramuscular tissue; your prescriber can advise on technique for your build.
After the injection, hold the pen in place until the indicator confirms the dose is complete, releasing it early is one of the most common causes of a partial dose. Do not rub the site afterwards; it is not necessary and can irritate the tissue.
A full step-by-step walkthrough of the injection process (including what to do if the pen feels faulty or the dose window shows unexpected colour) is on our how to inject tirzepatide in the stomach page. If something looks wrong with the pen before you use it, our guidance on faulty Mounjaro pens covers what to check and when to contact us. Storage between injections follows the Patient Information Leaflet exactly, always the definitive reference for temperature windows and handling details.
Mounjaro is a prescription medicine; where, how and when you inject should always be discussed with your prescriber if anything is unclear. If you are considering starting treatment, our free consultation connects you with a GPhC-registered prescriber who reviews your case the same working day.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.